Molecular Research within EMBRACE Studies BIO-EMBRACE-1

Size: px
Start display at page:

Download "Molecular Research within EMBRACE Studies BIO-EMBRACE-1"

Transcription

1 Molecular Research within EMBRACE Studies BIO-EMBRACE-1 Remi Nout, LUMC, Netherlands Supriya Chopra,Tata Memorial Centre, India

2 Biomarker Studies: Cervical Cancer Biological Variable Tumour Hypoxia ++ COX-2 ++ VEGF + HPV18 HPV Integration Site SOX-2/OCT-4 (Stem Cell)/CD44/CD66 + CXCR7 + DNA Ploidy + p53 + BCL-2 + EGFR - P16,21,27 - L1CAM/Vimentin/PDL-1/CD8+/CD14+ + Prognostic Variable All Studies in small cohorts <250 patients Gadducci et al, Critical Reviews in Hematology and Oncology,2013 Shen, Huang, J Histochemistry and Cytochemistry

3 Molecular Landscape of Cervical Cancer: TCGA Keratin Low Keratin High Adenocarcinoma Histology Squamous/?Adeno Squamous Adeno/Adenosqaumous/Sq HPV A9/ (HPV 16)++ A7 (HPV 18)++ A9 (HPV16)+++ A7(HPV18)+ A9/ (HPV 16)++ A7 (HPV 18)++ Methylation Intermediate/Low Intermediate/Low High Copy Number Copy Number High Copy Number High Low pi3akt Hormone EMT

4 PI3AKT EMT Pathway Based on small number of events (n=12) in 115 patients Cancer Genome Atlas Network, Nature 2017

5 Strengths within EMBRACE Study Group

6 IHC: Epithelial Mesenchymal Transition Leiden Group 6 Jordanova, with permission (under submission) Leiden 26-Mar-18

7 Diffuse PD-L1 expression and PD-L1 tumor associated macrophages 7 Heeren et al. Modern Pathology Mar-18

8 Local Relapse Free Survival: Tata CD44+ ESC+/CD44+ CD44- ESC+/CD44-91% vs 68% 96% vs 55%

9 Systemic- Inflammation- Immune Response Systemic Inflammation Immune Index HCC, Colorectal, Esophageal and Small Cell Lung cancer. Platelet Lymphocyte Ratio or Neutrophil Lymphocyte Ratio Balance between Host Inflammatory and Immune Response High Index : High Inflammatory Index (Expected to do worse) Low Index: Preserved Immune Response Platelets Neutrophils: Involved in VEGF/TGFBeta based Distant Metastasis Lymphocytes: Interferon based immune response, kill tumour cells

10 Disease free Survival: Systemic Inflammation Immune Index Low SII Index P=0.02 High SII Index Derived by Neutrophils, Lymphocytes and Platelets On Multivariate Analysis : Stage, ESC+/CD44- and Syst Inflammation/Immune Index

11 Aims Translational Research EMBRACE Confirm most relevant prognostic markers from TGCA/BioRAIDS Unique cohort: large, uniform selection and treatment (Retro)EMBRACE: paraffin embedded EMBRACE-II: paraffin embedded; opportunity to included frozen and blood

12 Strategy: Limited funding Start with pilot study Explore further options among centres within EMBRACE network related to ongoing research Apply for grant based on prelim results pilot work

13 Summary Survey 15 centers responded 14 interested for EMBRACE II prospective collection FFPE 13 interested to collect blood frozen etc. 13 would try for FFPE from EMBRACE I Majority would be able to ship out.

14 Name of Centre Survey: Tissue Based Research Paraffin Block EMBRACE Paraffin Block EMBRACE II Blood Frozen Biobankin g Facilities Ship to central Facility UMCU Y Y Y Y Y Y Leiden Y Y Y Y Y Y Osla Y Y Y Y Y Y Cross Cancer Y Y Another Facility. Need for funding Ljublajana (2) Y Y Y Y Y Y ACTREC,Tata Y Y Y Y Y N (Feasible with concrete proposal) MASTRO Y Y Y Y Y Y IGR Y Y Y Y Y Y Vienna Aarhus Yes, Response to survey awaited No, Need a concrete proposal to get legal approval to ship Addenbrokke Y Y Y Y Y Y Insti Claudius Y Y Y Y Y Y Navarra Y Y Y Y Y Y Erasmus MC Y Y Y Y Y Y McGill N Y N N N Y Y

15 BIOEMBRACE

16 Biomarkers to be performed Immunohistochemistry

17 Current Proposal Central IHC analysis for centers that can send out blank slides (N=5+1 H&E) from paraffin embeded tissue: Leiden Acces to Vectra multistainer 6-8 simultaneous IHC s on 1 blank slide

18 Shipping Requirements Funding for Shipping of slides is being organised by Study Chairs.. Shipping to: Leiden University Medical Centre Protocol: Detailed Shipping Address and Forms to be submitted along

19 Consent: (Retro)EMBRACE

20 IRB Approval EMBRACE II Prospectively Preserve Paraffin Blocks And optional Blood and Frozen Tissue Paraffin material already prospectively included in Informed Consent

21 Material Transfer Agreement

22 Consent for EMBRACEII Paraffin Block consent Difficulty in obtaining consent What % do not provide consent Storing blocks of EMBRACE II Leiden Yes Yes No Yes Tata Yes Yes No <10% Paraffin/Frozen /Blood Aarhus Yes Yes Institution also Vienna Yes Yes Some Variable Yes (?) Leeds Recruitment to be initiated Yes Llubjana Yes Yes :general consent No Not anticipated Not anticipated Yes No 0% No AMC,Netherlands Yes Yes No <10% No Alberta Recruitment to be initiated Oslo Yes As part of genral consent No reply No 6% Paraffin Frozen Cambridge Yes Yes No No No Mount Vernon Recruitment to be initiated Yes Recruitment to be initiated

23 Funding Application

BIO-EMBRACE-1 protocol version 1.4 date March 14, 2018

BIO-EMBRACE-1 protocol version 1.4 date March 14, 2018 BIO-EMBRACE-1 protocol version 1.4 date March 14, 2018 Title: Short Title A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally

More information

Nationwide Children s Hospital Biospecimen Core Resource Training

Nationwide Children s Hospital Biospecimen Core Resource Training Nationwide Children s Hospital Biospecimen Core Resource Training Team Science: A Collaboration in Medical Genomics Sponsored by the National Cancer Institute, the National Institutes of Health Nationwide

More information

The use of diagnostic FFPE material in cancer epidemiology research

The use of diagnostic FFPE material in cancer epidemiology research The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who

More information

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:

More information

Pathology of Inflammatory Breast Cancer (IBC) A rare tumor

Pathology of Inflammatory Breast Cancer (IBC) A rare tumor Pathology of Inflammatory Breast Cancer (IBC) A rare tumor Jelle Wesseling 1, John Martens 2, Gabe Sonke 1, Carolien Schröder 3 1: Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam

More information

Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12.

Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12. Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12. Non Cervical Cancers with an HPV aetiology 1. Anal 2. Penile 3. Vulval 4. Vaginal 5. Component of head

More information

PATHOLOGY WEBINAR. SESSION 2: March 20th, David Gandara, MD S1400 Study Co-Chair/UC Davis Comprehensive Cancer Center.

PATHOLOGY WEBINAR. SESSION 2: March 20th, David Gandara, MD S1400 Study Co-Chair/UC Davis Comprehensive Cancer Center. PATHOLOGY WEBINAR SESSION 2: March 20th, 2017 David Gandara, MD S1400 Study Co-Chair/UC Davis Comprehensive Cancer Center James Suh, MD Associate Medical Director and Molecular Pathologist/Foundation Medicine

More information

patients in the era of

patients in the era of Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.

More information

High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.

High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei

More information

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical

More information

EMBRACE II: Accreditation and patient accrual

EMBRACE II: Accreditation and patient accrual EMBRACE 9 th Annual Meeting Vienna Study Office EMBRACE II: Accreditation and patient accrual Centers recruiting and ready to recruit patients 16 centers have finished the accreditation process and are

More information

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification

More information

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis 5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory

More information

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19

More information

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

2015 EUROPEAN CANCER CONGRESS

2015 EUROPEAN CANCER CONGRESS 2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th

More information

Summary BREAST CANCER - Early Stage Breast Cancer... 3

Summary BREAST CANCER - Early Stage Breast Cancer... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential

More information

Informed Consent. Clinical Information

Informed Consent. Clinical Information IRB APPROVED MULTI-MEDIA SYSTEMS, INC. Form Revised March 2010 100 Radcliffe Drive, Chestertown, MD 21620 Tel: 866-ILS-1199/410-810-7506 Fax: 410-810-7508 Clinical Case Report (For Collection of Cancerous

More information

PD-L1 and Immunotherapy of GI cancers: What do you need to know

PD-L1 and Immunotherapy of GI cancers: What do you need to know None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives

More information

LSUHSC-OCHSNER Oncology Program Follow up Retreat March 6, :00 2:00 PM

LSUHSC-OCHSNER Oncology Program Follow up Retreat March 6, :00 2:00 PM LSUHSC-OCHSNER Oncology Program Follow up Retreat March 6, 2009 12:00 2:00 PM Ochsner s Brent House Caldwell/Burns Room - 2 nd Floor 1512 Jefferson Highway, New Orleans OBJECTIVES 1. Obtain information

More information

Molecular subtyping: how useful is it?

Molecular subtyping: how useful is it? Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure

More information

NCCTG Status Report for Study N May 2010

NCCTG Status Report for Study N May 2010 MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed

More information

Predictive Assays in Radiation Therapy

Predictive Assays in Radiation Therapy Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction

More information

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to

More information

Clasificación Molecular del Cáncer de Próstata. JM Piulats

Clasificación Molecular del Cáncer de Próstata. JM Piulats Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.

More information

CanAssist-Breast: New test for prediction of risk of recurrence in ER+/Her2- early stage breast cancer patients Manjiri Bakre, Ph.D.

CanAssist-Breast: New test for prediction of risk of recurrence in ER+/Her2- early stage breast cancer patients Manjiri Bakre, Ph.D. CanAssist-Breast: New test for prediction of risk of recurrence in ER+/Her2- early stage breast cancer patients Manjiri Bakre, Ph.D. Founder and CEO OncoStem Diagnostics Pvt. Ltd. Treatment Decision: HR+/HER2-

More information

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately

More information

RNA preparation from extracted paraffin cores:

RNA preparation from extracted paraffin cores: Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.

More information

Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D

Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Department of Radiation Oncology University of Florida College of Medicine Outline Objective

More information

The Cancer Genome Atlas

The Cancer Genome Atlas The Cancer Genome Atlas July 14, 2011 Kenna M. Shaw, Ph.D. Deputy Director The Cancer Genome Atlas Program TCGA: Core Objectives Launched in 2006 as a pilot and expanded in 2009, the goals of TCGA are

More information

Liverpool Ocular Oncology Biobank

Liverpool Ocular Oncology Biobank Liverpool Ocular Oncology Biobank Ocular Oncology NHS Specialised Services - national organisation responsible for the commissioning of specialised services that help improve the lives of children and

More information

Where We ve Been & Where We re Going SWOG FALL MEETING OCTOBER 5, 2018

Where We ve Been & Where We re Going SWOG FALL MEETING OCTOBER 5, 2018 Celebrating 4 Years of Lung MAP Where We ve Been & Where We re Going SWOG FALL MEETING OCTOBER 5, 2018 Slide 1 Lung MAP study leadership Vali Papadimitrakopoulou, MD study chair Roy Herbst, MD PhD study

More information

OMICS Journals are welcoming Submissions

OMICS Journals are welcoming Submissions OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible

More information

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately

More information

The Pathology of Neoplasia Part II

The Pathology of Neoplasia Part II The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology

More information

2015 EUROPEAN CANCER CONGRESS

2015 EUROPEAN CANCER CONGRESS 2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th

More information

Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology

Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor

More information

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell

More information

Barriers to Understanding

Barriers to Understanding Behind the Scenes: The Critical Importance of Cancer Cell Pathology and the Pathologist Sherry T. Emery, M.D., Chief of Pathology Northeast Health System Barriers to Understanding Questions for 2010 What

More information

Challenges for use of CTCs as a Diagnostic. Farideh Z. Bischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development Biocept, Inc.

Challenges for use of CTCs as a Diagnostic. Farideh Z. Bischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development Biocept, Inc. Challenges for use of CTCs as a Diagnostic Farideh Z. ischoff, Ph.D. Interim CSO Sr. Director, Translational Clinical Development iocept, Inc. Current Technology for CTC Testing Existing CTC testing platform

More information

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory

Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &

More information

Author's response to reviews

Author's response to reviews Author's response to reviews Title: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis Authors:

More information

The 8 th Edition of TNM for Lung Cancer: The IASLC Proposals.

The 8 th Edition of TNM for Lung Cancer: The IASLC Proposals. 13 th Cambridge Chest Meeting 2015. The 8 th Edition of TNM for Lung Cancer: The IASLC Proposals. Peter Goldstraw, Honorary Consultant Thoracic Surgeon, Royal Brompton Hospital, Emeritus Professor of Thoracic

More information

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Tumour Structure and Nomenclature Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Malignant Metastasis Core idea of cancer Normal Cell Slightly

More information

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.

More information

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE

More information

Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC

Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Translational Gastrointestinal Oncology Remond Fijneman r.fijneman@nki.nl Department of Pathology, Amsterdam, NL Wat is de potentiële waarde van ctdna?

More information

Qué hemos aprendido hasta hoy? What have we learned so far?

Qué hemos aprendido hasta hoy? What have we learned so far? Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.

More information

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios Kim-Anh LÊ CAO NHMRC Career Development Fellow, Statistician The University of Queensland Diamantina Institute

More information

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts

More information

Multiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD

Multiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD Multiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD Catholic Health Australia Symposium Mater Hospital, Brisbane 1 st June 2018 Why colorectal cancer?

More information

The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer

The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer Welcome! The Presence and Persistence of Resistant and Stem Cell- Like Tumor Cells as a Major Problem in Ovarian Cancer Prof. Sabine Kasimir-Bauer Department of Gynecology and Obstetrics University Hospital

More information

The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics

More information

PRESAGE CIVO: A NOVEL PLATFORM FOR PRECISION ONCOLOGY & DRUG DEVELOPMENT

PRESAGE CIVO: A NOVEL PLATFORM FOR PRECISION ONCOLOGY & DRUG DEVELOPMENT PRESAGE : A NOVEL PLATFORM FOR PRECISION ONCOLOGY & DRUG DEVELOPMENT DECEMBER 2017 Presage Biosciences, Inc. 2017. All rights reserved. Presage Proprietary Biosciences, information. Inc. 2017. All rights

More information

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,

More information

Personalized Therapy for Prostate Cancer due to Genetic Testings

Personalized Therapy for Prostate Cancer due to Genetic Testings Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center

More information

NGS ONCOPANELS: FDA S PERSPECTIVE

NGS ONCOPANELS: FDA S PERSPECTIVE NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration

More information

Emerging Tissue and Serum Markers

Emerging Tissue and Serum Markers Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice

More information

Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)

Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing

More information

CHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology. Non-clinical models: Tumour Models - Proof of Concept

CHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology. Non-clinical models: Tumour Models - Proof of Concept CHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology Non-clinical models: Tumour Models - Proof of Concept Edward C. Rosfjord Pfizer Worldwide R. & D. 14 December 2017

More information

Pre-Operative Assesment of Lymphocyte Monocyte Ratio in Ovarian Neoplasms. Athulya Krishna Kumar K.T*, Krishnaraj Upadhyaya and Vineeth G Nair

Pre-Operative Assesment of Lymphocyte Monocyte Ratio in Ovarian Neoplasms. Athulya Krishna Kumar K.T*, Krishnaraj Upadhyaya and Vineeth G Nair Original Article DOI: 10.21276/APALM.1919 Pre-Operative Assesment of Lymphocyte Monocyte Ratio in Ovarian Neoplasms Athulya Krishna Kumar K.T*, Krishnaraj Upadhyaya and Vineeth G Nair Department of Pathology,

More information

Aspects of Statistical Modelling & Data Analysis in Gene Expression Genomics. Mike West Duke University

Aspects of Statistical Modelling & Data Analysis in Gene Expression Genomics. Mike West Duke University Aspects of Statistical Modelling & Data Analysis in Gene Expression Genomics Mike West Duke University Papers, software, many links: www.isds.duke.edu/~mw ABS04 web site: Lecture slides, stats notes, papers,

More information

Comprehensive Tumor Profiling of Immune Response and Systems Biology. HTG EdgeSeq Immuno-Oncology Assay. HTG EdgeSeq Oncology Biomarker Panel

Comprehensive Tumor Profiling of Immune Response and Systems Biology. HTG EdgeSeq Immuno-Oncology Assay. HTG EdgeSeq Oncology Biomarker Panel Comprehensive Tumor Profiling of Immune Response and Systems Biology HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Oncology Biomarker Panel A new frontier in the research of cancer therapeutics HTG provides

More information

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer

More information

OverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA

OverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.

More information

The IO Quiz Show. The Complexity and Conundrums of the Tumor Microenvironment

The IO Quiz Show. The Complexity and Conundrums of the Tumor Microenvironment The IO Quiz Show The Complexity and Conundrums of the Tumor Microenvironment Sacha Gnjatic, PhD Associate Professor, Department of Medicine Division of Hematology And Medical Oncology Tisch Cancer Institute

More information

The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw

The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw Introduction The CRUK Stratified Medicine Programme: SMP1 rationale, design and implementation The role of the cellular

More information

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C. AD Award Number: W81XWH-08-1-0306 TITLE: Characterizing an EMT Signature in Breast Cancer PRINCIPAL INVESTIGATOR: Melanie C. Bocanegra CONTRACTING ORGANIZATION: Leland Stanford Junior University Stanford,

More information

Enterprise Interest Nothing to declare

Enterprise Interest Nothing to declare Enterprise Interest Nothing to declare Iulia Bârsan, MD, Lien Hoang, MD, Cristina Terinte, MD, Anna Pesci, MD, Sarit Aviel-Ronen, MD, Takako Kiyokawa, MD, Isabel Alvarado- Cabrero, MD, Esther Oliva, MD,

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as

More information

Head and Neck SCC. HPV in Tumors of the Head and Neck. Overview. Role of HPV in Pathogenesis of Head & Neck Tumors

Head and Neck SCC. HPV in Tumors of the Head and Neck. Overview. Role of HPV in Pathogenesis of Head & Neck Tumors HPV in Tumors of the Head and Neck Christina Kong, M.D. Associate Professor, Stanford Dept of Pathology Director, Cytopathology Laboratory & Cytopathology Fellowship ckong@stanford.edu Head and Neck SCC

More information

Drug Resistance: Oncology 520 March 27, 2012

Drug Resistance: Oncology 520 March 27, 2012 Drug Resistance: Oncology 520 March 27, 2012 John R. Mackey MD Medical Oncologist, Cross Cancer Institute Professor of Oncology University of Alberta john.mackey@albertahealthservices.ca Outline General

More information

NGS IN ONCOLOGY: FDA S PERSPECTIVE

NGS IN ONCOLOGY: FDA S PERSPECTIVE NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for

More information

How to address tumour heterogeneity in next generation oncology trials

How to address tumour heterogeneity in next generation oncology trials How to address tumour heterogeneity in next generation oncology trials Cihangir YANDIM, PhD Research Associate in Cancer Therapeutics and Clinical Sciences Dr. Cihangir Yandim - CTIP 2016, Hamburg 1 Founded

More information

How Changes in Central Cancer Registries are Impacting Cancer Research

How Changes in Central Cancer Registries are Impacting Cancer Research How Changes in Central Cancer Registries are Impacting Cancer Research Presented by: Thomas C. Tucker, PhD, MPH Director, Kentucky Cancer Registry University of Kentucky Kentucky Cancer Registry 29 th

More information

21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?

21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan? Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional

More information

Is there a Cookbook for Oncology Clinical Trials?

Is there a Cookbook for Oncology Clinical Trials? Masterclass for Masters See beyond : An Oncology Brainstorm Ghent, 16th of September 2016 Is there a Cookbook for Oncology Clinical Trials? Dimitrios Zardavas MD Associate Scientific Director, Breast International

More information

October Billing and compliance. Coagulation. Immunohistochemistry. Immunology. Referral testing ICD 10

October Billing and compliance. Coagulation. Immunohistochemistry. Immunology. Referral testing ICD 10 October 2015 Billing and compliance ICD 10 Coagulation Processing, transport and stability changes for multiple coagulation tests Immunohistochemistry IHC stain updates Immunology Lyme Western Blot testing

More information

mirna Dr. S Hosseini-Asl

mirna Dr. S Hosseini-Asl mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region

More information

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing

More information

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

chapter 4. The effect of oncogenic HPV on transformation zone epithelium chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence

More information

Introduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory

Introduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free

More information

2(iii): Prognostic biomarkers 2(iv): Biomarkers based on Cancer Types

2(iii): Prognostic biomarkers 2(iv): Biomarkers based on Cancer Types 15 August 2011 (Monday) Track 2(iii) 2(iv) 2(iii): Prognostic biomarkers 2(iv): Biomarkers based on Cancer Types Session Chair Dr. Jimmy Efird Brody School of Medicine, USA Session Co-Chair Dr. Shyamal

More information

Focus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct

Focus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley

More information

Regulatory Landscape for Precision Medicine

Regulatory Landscape for Precision Medicine Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What

More information

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery Screening for novel oncology biomarker panels using both DNA and protein microarrays John Anson, PhD VP Biomarker Discovery Outline of presentation Introduction to OGT and our approach to biomarker studies

More information

Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL

Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL email: r-nayar@northwestern.edu Nothing to disclose College of American Pathologists

More information

Immunohistochemical Expressions of AKT, ATM and Cyclin E in Oral Squamous Cell Carcinoma

Immunohistochemical Expressions of AKT, ATM and Cyclin E in Oral Squamous Cell Carcinoma Immunohistochemical Expressions of AKT, ATM and Cyclin E in Oral Squamous Cell Carcinoma Afrah A. Khalil, B.D.S., M.Sc. (1) Seta A. Sarkis, B.D.S., M.Sc., Ph.D. (2) ABSTRACT Background: Understanding the

More information

Staging Systems. Malcolm Mason UICC TNM Core Group and Cardiff University, UK

Staging Systems. Malcolm Mason UICC TNM Core Group and Cardiff University, UK Staging Systems Malcolm Mason UICC TNM Core Group and Cardiff University, UK Staging Systems 1943 Pierre Denoix, IGR UICC Committee 1950s 1968 First edition, Livre de Poche Other systems e.g. Dukes, FIGO

More information

Evolution of Pathology

Evolution of Pathology 1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy

More information

microrna Presented for: Presented by: Date:

microrna Presented for: Presented by: Date: microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions

More information

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical

More information

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon

More information

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health AD Award Number: W81XWH-12-1-0170 TITLE: Prospective Evaluation of Intraprostatic Inflammation and Focal Atrophy as a Predictor of Risk of High-Grade Prostate Cancer and Recurrence after Prostatectomy

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-16-1-0737 TITLE: Developing a PTEN-ERG Signature to Improve Molecular Risk Stratification in Prostate Cancer PRINCIPAL INVESTIGATOR: Tamara Lotan CONTRACTING ORGANIZATION: Johns Hopkins

More information

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com

More information